Document Detail


Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).
MedLine Citation:
PMID:  2501516     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
With data from 2 large randomized British Medical Research Council studies we identified several factors influencing the recurrence of newly diagnosed superficial bladder cancer. Using multivariate methods to assess the relative importance of these factors we found the most important to be the result of cystoscopy performed 3 months after initial transurethral resection and the number of tumors (single or multiple) at presentation. With these 2 factors we divided the patient population into 3 groups with varying degrees of prognosis. Different followup procedures are proposed for each of these 3 groups.
Authors:
M K Parmar; L S Freedman; T B Hargreave; D A Tolley
Related Documents :
12113086 - Retinoids in the prevention of bladder cancer.
21960356 - Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created f...
12184646 - Arsenic keratosis and pigmentation accompanied by multiple bowen's disease and genitour...
22212706 - Psychological aspects of prostate cancer: a clinical review.
16737666 - Can manual treatment of lymphedema promote metastasis?
21995576 - Chronic inflammation and immunologic-based constraints in malignant disease.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of urology     Volume:  142     ISSN:  0022-5347     ISO Abbreviation:  J. Urol.     Publication Date:  1989 Aug 
Date Detail:
Created Date:  1989-08-25     Completed Date:  1989-08-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376374     Medline TA:  J Urol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  284-8     Citation Subset:  AIM; IM    
Affiliation:
MRC Cancer Trials Office, Cambridge, United Kingdom.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravesical
Carcinoma, Transitional Cell / drug therapy,  mortality*
Cystoscopy*
Follow-Up Studies
Humans
Mitomycin
Mitomycins / therapeutic use
Multicenter Studies as Topic
Neoplasm Recurrence, Local*
Prognosis
Statistics as Topic
Thiotepa / therapeutic use
Time Factors
Urinary Bladder Neoplasms / drug therapy,  mortality*
Chemical
Reg. No./Substance:
0/Mitomycins; 50-07-7/Mitomycin; 52-24-4/Thiotepa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  In vitro processing of dengue virus structural proteins: cleavage of the pre-membrane protein.
Next Document:  The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in...